Download Results
2 research outcomes, page 1 of 1
  • publication . Article . 2019
    Open Access
    Authors:
    Colin Hessel; Michael J. Morris; Joel Picus; Darren R. Feldman; Daniel J. George; Toni K. Choueiri; Susan Halabi; Christian Scheffold; Shaker R. Dakhil; Olwen Hahn; ...
    Publisher: Wiley
    Project: NIH | Network Lead Academic Par... (3U10CA180791-04S1), NIH | Washington University/ Si... (5U10CA180833-05), NIH | OSU as Network Lead Acade... (1U10CA180850-01), NIH | Statistics and Data Cente... (5U10CA180882-02), NIH | Alliance for Clinical Tri... (3U10CA180821-02S2), NIH | NCI National Clinical Tri... (5U10CA180857-02), NIH | MOUSE GENETICS (2P30CA008748-43), NIH | NCTN Lead Academic Partic... (5U10CA180867-04)

    Abstract Cabozantinib treatment prolonged progression‐free survival (PFS) and improved objective response rate (ORR) compared with sunitinib in patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk by International Metastatic Renal Cell Carcinom...

  • publication . Article . 2018
    Open Access English
    Authors:
    M. Sitiki Copur; Craig A. Bunnell; Hyman B. Muss; Arti Hurria; Jennifer Le-Rademacher; Gretchen Kimmick; Bhuvaneswari Ramaswamy; Harvey J. Cohen; Stuart M. Lichtman; Myra F. Barginear; ...
    Publisher: John Wiley & Sons, Inc.
    Project: NIH | OSU as Network Lead Acade... (1U10CA180850-01), NIH | Delaware/Christiana Care ... (5UG1CA189819-05), NIH | NCI National Clinical Tri... (5U10CA180857-02), NIH | Naional Cancer Institute,... (5U10CA180790-03), NIH | Alliance NCORP Research B... (5UG1CA189823-04), NIH | Network Lead Academic Par... (3U10CA180791-04S1), NIH | North Shore-LIJ Health Sy... (5UG1CA189850-05), NIH | NCTN Lead Academic Partic... (5U10CA180867-04), NIH | NCTN Lead Academic Partic... (5U10CA180838-05), NIH | MOUSE GENETICS (2P30CA008748-43)

    Abstract Purpose. A few previous studies report a direct relationship between older age and chemotherapy‐induced neuropathy. This study further evaluated this adverse event's age‐based risk. Methods. CALGB 40101 investigated adjuvant paclitaxel (80 mg/m2 once per week o...

2 research outcomes, page 1 of 1